TScan Therapeutics eyes Phase 3 TCR-T launch in Q2 with $128m cash
TScan Therapeutics (Nasdaq: TCRX) has set out an ambitious mid-2026 milestone schedule, anchored by the planned initiation of a Phase 3 trial of its lead T cell receptor-engineered T cell (TCR-T) therapy, TSC-101, in patients with acute myeloid leukaemia and myelodysplastic syndrome undergoing allogeneic haematopoietic cell transplantation (HCT).
The Waltham, Massachusetts company also expects to share early data from Cohort C of its ongoing ALLOHA Phase 1 trial in the second quarter. Cohort C has enrolled and treated more than ten patients using what TScan describes as a commercial-ready manufacturing process — a detail the company is leaning on as it transitions toward a pivotal study.
Pipeline milestones
Beyond TSC-101, TScan plans to broaden its haematology franchise with two additional TCR-T candidates. TSC-102-A01 and TSC-102-A03 both target the surface antigen CD45 and are restricted to the HLA types A\01:01 and A\03:01, respectively. The company expects to open a Phase 1 study for both candidates in the second half of 2026. Chief Medical Officer Chrystal U. Louis said the two programmes together could "approximately double the number of patients who could potentially benefit from TCR-T therapy following allogeneic transplant" — an assertion that reflects HLA haplotype prevalence modelling but has not yet been tested in the clinic.
Preclinical identification and characterisation data for TSC-102-A01 and TSC-102-A03 will be presented by poster at the American Society of Gene and Cell Therapy annual meeting in Boston, running 11–15 May 2026.
TScan is also maintaining early-stage work in solid tumours, where it is developing in vivo TCR-T engineering methods, and in autoimmunity, where it expects to share preclinical proof-of-concept data in the second half of 2026. Neither programme has advanced to human studies.
Financial position
First-quarter 2026 revenue was $1.0 million, down from $2.2 million in the comparable period of 2025, reflecting the timing of research activities under the company's collaboration agreement with Amgen. R&D expenditure fell to $21.9 million from $29.8 million a year earlier — a reduction the company attributed partly to supply and consumable timing and partly to a deliberate strategic decision to prioritise the haematology programme. Net loss narrowed to $28.7 million from $34.1 million.
Cash and cash equivalents stood at $128.1 million as of 31 March 2026, which the company says is sufficient to fund operations into the second half of 2027.
Market context
The allogeneic HCT setting has become a focal point for adoptive cell therapy developers seeking defined patient populations where engraftment dynamics and residual disease create a plausible treatment window. TScan's HLA-restricted TCR-T approach competes conceptually with donor-derived and off-the-shelf strategies from a number of academic spinouts and larger cell therapy developers, including players pursuing CAR-T and gamma-delta T cell programmes in the post-transplant space. The advantage of HLA restriction is target specificity; the limitation is the eligible population ceiling, which is precisely why TScan is adding A\01:01 and A\03:01 coverage to complement its existing antigen targeting.
The planned Phase 3 launch will be closely watched not only for enrolment pace — which is often the rate-limiting step in HCT-adjacent trials — but also for the endpoint design TScan ultimately agrees with regulators. Overall survival data in this setting can take years to mature; an event-free survival or relapse-incidence primary endpoint would offer a faster readout but may face greater scrutiny from the FDA.